Published in Br J Pharmacol on November 24, 2014
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med (2015) 0.94
Inflammation, metaflammation and immunometabolic disorders. Nature (2017) 0.93
Maladaptive Modulations of NLRP3 Inflammasome and Cardioprotective Pathways Are Involved in Diet-Induced Exacerbation of Myocardial Ischemia/Reperfusion Injury in Mice. Oxid Med Cell Longev (2015) 0.79
Nonerythropoietic Erythropoietin-Derived Peptide Suppresses Adipogenesis, Inflammation, Obesity and Insulin Resistance. Sci Rep (2015) 0.78
Sulforaphane improves dysregulated metabolic profile and inhibits leptin-induced VSMC proliferation: Implications toward suppression of neointima formation after arterial injury in western diet-fed obese mice. J Nutr Biochem (2016) 0.77
Targeting the NLRP3 inflammasome to reduce diet-induced metabolic abnormalities in mice. Mol Med (2015) 0.77
Plant-Produced Asialo-Erythropoietin Restores Pancreatic Beta-Cell Function by Suppressing Mammalian Sterile-20-like Kinase (MST1) and Caspase-3 Activation. Front Pharmacol (2017) 0.75
The Protective Effects of Helix B Surface Peptide on Experimental Acute Liver Injury Induced by Carbon Tetrachloride. Dig Dis Sci (2017) 0.75
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1996) 26.30
Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol (2010) 17.30
Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol (2010) 13.76
Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med (2006) 10.65
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res (2013) 9.61
Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem (2003) 5.86
The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol (2013) 5.57
Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev (2008) 4.87
Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science (2004) 4.09
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A (2004) 3.40
The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab (2008) 3.34
Transcriptional control of mitochondrial biogenesis and function. Annu Rev Physiol (2009) 2.76
High-fat diets cause insulin resistance despite an increase in muscle mitochondria. Proc Natl Acad Sci U S A (2008) 2.65
Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med (2008) 2.55
The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol (2013) 2.29
Insulin signaling diverges into Akt-dependent and -independent signals to regulate the recruitment/docking and the fusion of GLUT4 vesicles to the plasma membrane. Mol Biol Cell (2006) 2.27
Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann N Y Acad Sci (2008) 2.27
Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes (2006) 2.24
Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A (2008) 2.21
Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol (2012) 2.18
Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes (2007) 2.13
The Concise Guide to PHARMACOLOGY 2013/14: transporters. Br J Pharmacol (2013) 2.07
Muscles and their myokines. J Exp Biol (2011) 2.07
Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol (2012) 1.67
Raising plasma fatty acid concentration induces increased biogenesis of mitochondria in skeletal muscle. Proc Natl Acad Sci U S A (2007) 1.58
siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-2/Akt1 in glucose and lipid metabolism in human skeletal muscle. Cell Metab (2006) 1.48
Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One (2009) 1.44
The influence of different fixatives and fixation methods on the ultrastructure of rat kidney proximal tubule cells. II. Effects of varying osmolality, ionic strength, buffer system and fixative concentration of glutaraldehyde solutions. J Ultrastruct Res (1966) 1.41
Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int (2013) 1.37
Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes (2008) 1.34
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med (2012) 1.33
Anemia and the role of erythropoietin in diabetes. J Diabetes Complications (2006) 1.22
The receptor that tames the innate immune response. Mol Med (2012) 1.19
Anemia and diabetes in the absence of nephropathy. Diabetes Care (2005) 1.13
ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice. Anesthesiology (2011) 1.11
Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol (2010) 1.07
Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes (2011) 1.06
IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor. Vitam Horm (2006) 1.04
Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism (2010) 1.03
Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care (2011) 1.03
ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs (2014) 0.97
Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am J Nephrol (1996) 0.95
Erythropoietin inhibits gluconeogenesis and inflammation in the liver and improves glucose intolerance in high-fat diet-fed mice. PLoS One (2013) 0.95
Endogenous erythropoietin signaling facilitates skeletal muscle repair and recovery following pharmacologically induced damage. FASEB J (2012) 0.93
ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury. J Transl Med (2013) 0.93
Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the β-common receptor. Dis Model Mech (2013) 0.92
Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-δ agonism correlates with impaired NLRP3 inflammasome activation. Biochem Pharmacol (2012) 0.91
High sugar intake and development of skeletal muscle insulin resistance and inflammation in mice: a protective role for PPAR- δ agonism. Mediators Inflamm (2013) 0.91
Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Exp Neurol (2011) 0.90
Erythropoietin induces a shift of muscle phenotype from fast glycolytic to slow oxidative. Int J Sports Med (2007) 0.90
Erythropoietin signaling: a novel regulator of white adipose tissue inflammation during diet-induced obesity. Diabetes (2014) 0.88
The high prevalence of anemia in diabetes is linked to functional erythropoietin deficiency. Semin Nephrol (2006) 0.88
Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns. Proc Natl Acad Sci U S A (2013) 0.88
The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin. Horm Metab Res (2004) 0.88
Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse. Am J Physiol Renal Physiol (2013) 0.86
Metabolic effects of erythropoietin in patients on peritoneal dialysis. Pediatr Nephrol (1998) 0.85
The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model. Neuroscience (2012) 0.83
Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron (2000) 0.83
Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis. Pharmacotherapy (2009) 0.83
Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients. Hemodial Int (2009) 0.83
The effect of recombinant human erythropoietin treatment on insulin resistance and inflammatory markers in non-diabetic patients on maintenance hemodialysis. Hippokratia (2008) 0.83
Knockdown of NYGGF4 increases glucose transport in C2C12 mice skeletal myocytes by activation IRS-1/PI3K/AKT insulin pathway. J Bioenerg Biomembr (2012) 0.82
Ketamine does not produce relief of neuropathic pain in mice lacking the β-common receptor (CD131). PLoS One (2013) 0.79
The erythropoietin-derived peptide mimetic pHBSP affects cellular and cognitive consequences in a rat post-status epilepticus model. Epilepsia (2011) 0.79
Potential role of erythropoietin receptors and ligands in attenuating apoptosis and inflammation in critical limb ischemia. J Vasc Surg (2013) 0.78
Obesity-related renal damage: changing diet to avoid progression. Kidney Int (2010) 0.78
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A (1993) 4.82
Statistical analysis of denaturing gel electrophoresis (DGE) fingerprinting patterns. Environ Microbiol (2002) 2.75
The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A (1995) 2.36
Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol (1993) 2.32
Membrane-permeable radical scavenger, tempol, reduces multiple organ injury in a rodent model of gram-positive shock. Crit Care Med (2000) 2.13
Mechanism of gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J Exp Med (1998) 2.08
Phylogenetic position of the genus Hydrogenobacter. Int J Syst Bacteriol (1994) 1.98
Endothelial cells metabolize NG-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine. Biochem Biophys Res Commun (1990) 1.94
MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res (1999) 1.90
Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci U S A (1994) 1.83
Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations. J Thromb Haemost (2010) 1.71
Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br J Pharmacol (1995) 1.67
Time course and mechanism of oxidative stress and tissue damage in rat liver subjected to in vivo ischemia-reperfusion. J Clin Invest (1993) 1.66
Release of histamine from rat mast cells by acetylcholine. Nature (1978) 1.62
Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. Infect Immun (2000) 1.58
Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the rat. Crit Care Med (2001) 1.55
Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney Int (2000) 1.52
Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol (1993) 1.51
The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock. Crit Care Med (2001) 1.50
Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J (2005) 1.49
Calcium-dependent diuretic system in preascitic liver cirrhosis. J Hepatol (2010) 1.42
Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res (1993) 1.29
Characteristics of histamine release evoked by acetylcholine in isolated rat mast cells. J Physiol (1980) 1.27
Production and consumption of hydrogen in a eutrophic lake. Appl Environ Microbiol (1983) 1.24
Lipocortin 1 mediates the inhibition by dexamethasone of the induction by endotoxin of nitric oxide synthase in the rat. Proc Natl Acad Sci U S A (1995) 1.24
Micromorphology of Gram-negative hydrogen bacteria. II. Cell envelope, membranes, and cytoplasmic inclusions. Arch Microbiol (1977) 1.23
Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. Proc Natl Acad Sci U S A (1994) 1.23
Calpain inhibitor I reduces the activation of nuclear factor-kappaB and organ injury/dysfunction in hemorrhagic shock. FASEB J (2001) 1.23
Expression of histocompatibility antigen HLA-DR by salivary gland epithelial cells in Sjögren's syndrome. Arthritis Rheum (1986) 1.22
Delayed circulatory failure due to the induction of nitric oxide synthase by lipoteichoic acid from Staphylococcus aureus in anaesthetized rats. Br J Pharmacol (1995) 1.22
H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol (2003) 1.20
Incomplete inhibition of the pressor effects of endothelin-1 and related peptides in the anaesthetized rat with BQ-123 provides evidence for more than one vasoconstrictor receptor. Br J Pharmacol (1993) 1.18
Invited opinion: role of nitric oxide in hemorrhagic, traumatic, and anaphylactic shock and thermal injury. Shock (1994) 1.18
Micromorphology of Gram-negative hydrogen bacteria. I. Cell morphology and flagellation. Arch Microbiol (1977) 1.18
Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br J Pharmacol (1995) 1.16
Nifedipine inhibits the induction of nitric oxide synthase by bacterial lipopolysaccharide. J Pharmacol Exp Ther (1993) 1.14
Oxidative and nitrosative stress in brain mitochondria of diabetic rats. J Endocrinol (2005) 1.14
Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture. Hypertension (1998) 1.13
Trauma alarmins as activators of damage-induced inflammation. Br J Surg (2012) 1.13
Modulation of the spontaneous histamine release by adrenergic and cholinergic drugs. Agents Actions (1978) 1.11
Effects of estrogen on the vascular system. Braz J Med Biol Res (2003) 1.11
Isolation of Thermus strains from hot composts (60 to 80 degrees C). Appl Environ Microbiol (1996) 1.10
Isolation and characterization of highly thermophilic xylanolytic Thermus thermophilus strains from hot composts. Can J Microbiol (2000) 1.09
Analysis of the signal transduction in the induction of nitric oxide synthase by lipoteichoic acid in macrophages. Br J Pharmacol (1996) 1.09
Tempol reduces infarct size in rodent models of regional myocardial ischemia and reperfusion. Free Radic Biol Med (1999) 1.07
Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. Biochem Biophys Res Commun (1993) 1.07
Effect of calpain inhibitor I, an inhibitor of the proteolysis of I kappa B, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. Br J Pharmacol (1997) 1.06
Role of nitric oxide in the circulatory failure and organ injury in a rodent model of gram-positive shock. Br J Pharmacol (1996) 1.05
Calpain inhibitor I reduces the development of acute and chronic inflammation. Am J Pathol (2000) 1.05
Effects of tempol, a membrane-permeable radical scavenger, in a gerbil model of brain injury. Brain Res (2000) 1.05
Endothelium-derived relaxing factor participates in the increased blood flow in response to pentagastrin in the rat stomach mucosa. Proc Biol Sci (1990) 1.04
Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo. Eur J Pharmacol (1993) 1.04
Ischemic preconditioning: a defense mechanism against the reactive oxygen species generated after hepatic ischemia reperfusion. Transplantation (2002) 1.04
Induction of NO synthesis by lipoteichoic acid from Staphylococcus aureus in J774 macrophages: involvement of a CD14-dependent pathway. Biochem Biophys Res Commun (1997) 1.03
GAS6 inhibits granulocyte adhesion to endothelial cells. Blood (1998) 1.02
Effect of interleukin-4 and interleukin-10 on leucocyte migration and nitric oxide production in the mouse. Br J Pharmacol (1995) 1.02
The involvement of endothelium-derived relaxing factor in the regulation of renal cortical blood flow in the rat. Br J Pharmacol (1991) 1.02
The hemodynamic effects of endothelin-1 in the pithed rat. J Cardiovasc Pharmacol (1989) 1.02
Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase. Br J Pharmacol (1997) 1.02
Glibenclamide-induced inhibition of the expression of inducible nitric oxide synthase in cultured macrophages and in the anaesthetized rat. Br J Pharmacol (1995) 1.01
Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine. Cancer Res (1994) 1.01
Dihydropyridine antagonists and agonists of calcium channels inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Biochem Biophys Res Commun (1993) 1.01
Cholinergic histamine release: evidence of muscarinic receptors in rat mast cells [proceedings]. Agents Actions (1979) 1.00
Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. Gut (2001) 0.99
Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension (2001) 0.99
Tachykinins activate guinea-pig alveolar macrophages: involvement of NK2 and NK1 receptors. Br J Pharmacol (1990) 0.98
Clonidine and naloxone-induced opiate withdrawal: a comparison between clonidine and morphine in man. Subst Alcohol Actions Misuse (1980) 0.98
Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production. Scand J Immunol (2001) 0.98
Peptidoglycan primes for LPS-induced release of proinflammatory cytokines in whole human blood. Shock (2001) 0.98
Lipoteichoic acid induces delayed protection in the rat heart: A comparison with endotoxin. Arterioscler Thromb Vasc Biol (2000) 0.98
Inhibition of glycogen synthase kinase-3beta attenuates the development of carrageenan-induced lung injury in mice. Br J Pharmacol (2006) 0.97
Calpain inhibitor-1 reduces renal ischemia/reperfusion injury in the rat. Kidney Int (2001) 0.97
Endotoxin induces a second window of protection in the rat heart as determined by using p-nitro-blue tetrazolium staining, cardiac troponin T release, and histology. Arterioscler Thromb Vasc Biol (1999) 0.97
Inhibition by spermine of the induction of nitric oxide synthase in J774.2 macrophages: requirement of a serum factor. Br J Pharmacol (1994) 0.96
Role of IL-6 in the pleurisy and lung injury caused by carrageenan. J Immunol (1999) 0.96
Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney. Br J Pharmacol (1994) 0.96
Decline in the expression of copper/zinc superoxide dismutase in the kidney of rats with endotoxic shock: effects of the superoxide anion radical scavenger, tempol, on organ injury. Br J Pharmacol (1998) 0.96
Histamine release by vagal stimulation. Agents Actions (1983) 0.96
Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone. J Physiol Pharmacol (1997) 0.96
The effects of endothelium-dependent vasodilators on cardiac output and their distribution in the anaesthetized rat: a comparison with sodium nitroprusside. Br J Pharmacol (1988) 0.95
Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock. Br J Pharmacol (2000) 0.95
Involvement of tyrosine kinase in the induction of cyclo-oxygenase and nitric oxide synthase by endotoxin in cultured cells. Br J Pharmacol (1994) 0.95
Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Br J Pharmacol (1995) 0.95
Characterization of ionotropic glutamate receptors in human lymphocytes. Br J Pharmacol (2001) 0.95
Role for endothelial nitric oxide synthase in nitrite-induced protection against renal ischemia-reperfusion injury in mice. Nitric Oxide (2009) 0.94
Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol (2001) 0.94
Associated changes of lipid peroxidation and transforming growth factor beta1 levels in human colon cancer during tumour progression. Gut (2002) 0.94
High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB J (2001) 0.94
Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler (1999) 0.94
Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol (1999) 0.94
Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension (2001) 0.94
An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood (1999) 0.94
Cytokine-mediated induction of cyclo-oxygenase-2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide. Br J Pharmacol (1995) 0.94
Effects of tempol, a membrane-permeable radical scavenger, in a rodent model of carrageenan-induced pleurisy. Eur J Pharmacol (2000) 0.94
Nitric oxide synthase in the rat fallopian tube is regulated during the oestrous cycle. J Endocrinol (1995) 0.93
Activation of soluble guanylyl cyclase by a factor other than nitric oxide or carbon monoxide contributes to the vascular hyporeactivity to vasoconstrictor agents in the aorta of rats treated with endotoxin. Biochem Biophys Res Commun (1994) 0.93
Comparison of the induction of cyclooxygenase and nitric oxide synthase by endotoxin in endothelial cells and macrophages. Eur J Pharmacol (1995) 0.93